



02-09-05

IFW IMAGE

Practitioner's Packet No. **MPI97-035CP3M**

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Acton, Susan et al.

Application No.: 09/635,501

Group No.: 1654

Filed: August 9, 2000

Examiner: Chism, Billy D.

For: ANGIOTENSIN CONVERTING ENZYME HOMOLOG AND USES THEREFOR

**Commissioner for Patents**

**P.O. Box 1450**

**Alexandria, VA 22313-1450**

**SUBMISSION OF FORMAL DRAWINGS**

1. In response to the Notice Regarding Drawings mailed January 19, 2005, and to correct the margins and character of lines, numbers and letters as noted in the Notice of Draftsperson's Patent Drawing Review dated August 9, 2000, Applicants submit herewith 23 sheets of formal drawings for filing in this application (Figures 1A-1B, 2A-2D, 3A-3C, 4, 5A-5B, 6A-6B, 7A-7B, 8, 9A-9B, 10A-10B, 11A-11C, 12, 13A-13B).

2. The two month period of response set in the Notice expires on March 19, 2005. This submission is on or before this expiry date.

3. A copy of the Notice Regarding Drawings mailed January 19, 2005, and the Notice of Draftsperson's Patent Drawing Review dated August 9, 2000, are enclosed herewith.

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

**37 C.F.R. SECTION 1.8(a)**


**37 C.F.R. SECTION 1.10\***

☐ with sufficient postage as first class mail.

☒ as "Express Mail Post Office to Addressee"  
Mailing Label No. EV621834845US

**TRANSMISSION**

☐ transmitted by facsimile to the Patent and Trademark Office.

  
Signature

Date: February 8, 2005

Sean Hunziker

(type or print name of person certifying)


**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. MPI97-035CP3M**

4. It is believed no fee is due in connection with this submission. However, in the event any fees are due, the Commissioner is hereby authorized to charge Account No. 501668 for any fee deficiency due resulting from the filing of this paper.

February 8, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By   
Kerri Pollard Schray  
Registration No. 47,066  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone – (617) 551-3676  
Facsimile – (617) 551-8820



**COPY**



**UNITED STATES PATENT AND TRADEMARK OFFICE**

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND  
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

|  |
|--|
| RECEIVED<br>MILLENNIUM PHARMACEUTICALS<br>JAN 25 2005<br>DOCKETING DEPARTMENT<br>DOCKETED BY: <i>[Signature]</i> |
|--|

|   |  |   |   |
|---|--|---|---|
| APPLICATION NUMBER<br><b>09/635,501</b> | FILING/RECEIPT DATE<br><b>08/09/00</b> | FIRST NAMES APPLICANT<br><b>Susan Acton</b> | ATTORNEY DOCKET NUMBER<br><b>MNI-132CP3</b> |
|---|--|---|---|

INTELLECTUAL PROPERTY GROUP  
MILLENNIUM PHARMACEUTICAL, INC.  
75 SIDNEY STREET  
CAMBRIDGE, MA 02139

Examiner  
CHISM  
Art Unit  
1654

Paper Number

Date Mailed: 01-19-05

## Notice Regarding Drawings

Corrected drawings for the above-identified application, received in the USPTO on 08/09/00 are still not acceptable for the reason(s) identified on the attached PTO-948. Applicant is given one opportunity to correct the informalities within a two-month time period from the mailing date of this notice. **THIS TIME PERIOD IS NOT EXTENDABLE UNDER EITHER 37 CFR 1.136(a) OR 1.136(b).** Failure to take corrective action within the set period will result in abandonment of the application.

ATTACHMENT: PTO-948 Notice of Draftsperson's Patent Review

**RETURN CORRECTED DRAWINGS TO:**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

ANHDAO DOAN  
703 - 305 - 0896

# COPY



Form PTO-948 (Rev. 06/00)  
Application No. 09/635581

U.S. DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office

## NOTICE OF DRAFTSPERSON'S PATENT DRAWING REVIEW

The drawing(s) filed (insert date) 8/9/00 are:

- A. ☐ approved by the Draftsperson under 37 CFR 1.84 or 1.152.  
B. ☒ objected to by the Draftsperson under 37 CFR 1.84 or 1.152 for the reasons indicated below. Corrected drawings are required.

**1. DRAWINGS.** 37 CFR 1.84(a): Acceptable categories of drawings: Black ink or Color (3 sets required).

☐ Color drawings are not acceptable until petition is granted. Fig(s) \_\_\_\_\_  
☐ Pencil and non black ink not permitted. Fig(s) \_\_\_\_\_

**2. PHOTOGRAPHS.** 37 CFR 1.84(b)

☐ One (1) full-tone set is required. Fig(s) \_\_\_\_\_  
☐ Photographs may not be mounted. 37 CFR 1.84(e)  
☐ Photographs must meet paper size requirements of 37 CFR 1.84(f). Fig(s) \_\_\_\_\_  
☐ Poor quality (half-tone). Fig(s) \_\_\_\_\_

**3. TYPE OF PAPER.** 37 CFR 1.84(e)

☐ Paper not flexible, strong, white, and durable. Fig(s) \_\_\_\_\_  
☐ Erasures, alterations, overwritings, interlineations, folds, copy machine marks not accepted. Fig(s) \_\_\_\_\_

**4. SIZE OF PAPER.** 37 CFR 1.84(f): Acceptable sizes:

21.0 cm by 29.7 cm (DIN size A4) or  
21.6 cm by 27.9 cm (8 1/2 x 11 inches)  
☐ All drawing sheets not the same size.  
Sheet(s) \_\_\_\_\_

☐ Drawings sheets not an acceptable size. Fig(s) \_\_\_\_\_

**5. MARGINS.** 37 CFR 1.84(g): Acceptable margins:

Top 2.5 cm Left 2.5 cm Right 1.5 cm Bottom 1.0 cm

Margins not acceptable. Fig(s) 2A, 2B, 3A, 3C, 5-13B  
☒ Top (T) ☒ Left (L)  
☐ Right (R) ☐ Bottom (B)

**6. VIEWS.** 37 CFR 1.84(h)

REMINDER: Specification may require revision to correspond to drawing changes, e.g., if Fig. 1 is changed to Fig. 1A, Fig. 1B and Fig. 1C, etc., the specification, at the Brief Description of the Drawings, must likewise be changed.

☐ Views not labeled separately or properly. Fig(s) \_\_\_\_\_

**7. SECTIONAL VIEWS.** 37 CFR 1.84(h)(3)

☐ Sectional designation should be noted with Arabic or Roman numbers. Fig(s) \_\_\_\_\_

**8. ARRANGEMENT OF VIEWS.** 37 CFR 1.84(i)  
☐ Words do not appear on a horizontal, left-to-right fashion when page is either upright or turned so that the top becomes the right side, except for graphs. Fig(s) \_\_\_\_\_

**9. SCALE.** 37 CFR 1.84(k)

☐ Scale not large enough to show mechanism without crowding when drawing is reduced in size to two-thirds in reproduction. Fig(s) \_\_\_\_\_

**10. CHARACTER OF LINES, NUMBERS, & LETTERS.** 37 CFR 1.84(l)

☒ Lines, numbers & letters not uniformly thick and well defined, clear, durable, and black (poor line quality). Fig(s) 1A-13B

**11. SHADING.** 37 CFR 1.84(m)

☐ Solid black areas pale. Fig(s) \_\_\_\_\_  
☐ Solid black shading not permitted. Fig(s) \_\_\_\_\_

**12. NUMBERS, LETTERS, & REFERENCE CHARACTERS.** 37 CFR 1.84(p)

☐ Numbers and reference characters not plain and legible. Fig(s) \_\_\_\_\_  
☐ Figure legends are poor. Fig(s) \_\_\_\_\_  
☐ Numbers and reference characters not oriented in the same direction as the view. 37 CFR 1.84(p)(1) Fig(s) \_\_\_\_\_  
☐ English alphabet not used. 37 CFR 1.84(p)(2) Fig(s) \_\_\_\_\_

☐ Numbers, letters and reference characters must be at least 32 cm (1/8 inch) in height. 37 CFR 1.84(p)(3). Fig(s) \_\_\_\_\_

**13. LEAD LINES.** 37 CFR 1.84(q)

☐ Lead lines missing. Fig(s) \_\_\_\_\_

**14. NUMBERING OF SHEETS OF DRAWINGS.**

37 CFR 1.84(t)

☐ Sheets not numbered consecutively, and in Arabic numbers beginning with number 1. Sheet(s) \_\_\_\_\_

**15. NUMBERING OF VIEWS.** 37 CFR 1.84(u)

☐ Views not numbered consecutively, and in Arabic numerals, beginning with number 1. Fig(s) \_\_\_\_\_

**16. DESIGN DRAWINGS.** 37 CFR 1.152

☐ Surface shading shown not appropriate. Fig(s) \_\_\_\_\_  
☐ Solid black surface shading is not permitted except when used to represent the color black as well as color contrast. Fig(s) \_\_\_\_\_

COMMENTS:

Reviewer A.D.

If you have questions, call (703) 305-8404.

Date 1/19/05

Attachment to Paper No. \_\_\_\_\_

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In application of: Acton, Susan et al.

Application No.: 09/635,501

Group No.: 1654

Filed: August 9, 2000

Examiner: Chism, Billy D.

For: ANGIOTENSIN CONVERTING ENZYME HOMOLOG AND USES THEREFOR

**Commissioner for Patents**

**P.O. Box 1450**

**Alexandria, VA 22313-1450**

**TRANSMITTAL**

1. Transmitted herewith for this application is/are:
  - a. This Transmittal (1 page - in duplicate);
  - b. Submission of Formal Drawings (2 pages);
  - c. Formal Drawings (23 sheets - Figs. 1A-13B);
  - d. Copy of Notice Regarding Drawings mailed January 19, 2005 (1 page);
  - e. Copy of Notice of Draftsperson's Patent Drawing Review (1 page); and
  - f. Return Postcard.

**STATUS**

2. Applicant is other than a small entity.


**FEE DEFICIENCY**

3. If any fees are required, charge Account No. 501668.

February 8, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By



Kerri Pollard Schray  
Reg. No. 47,066  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - (617) 551-3676  
Facsimile - (617) 551-8820

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

- ☐ with sufficient postage as first class mail.
- ☒ as "Express Mail Post Office to Addressee"  
Mailing Label No. EV621834845US

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

  
Signature

Date: February 8, 2005

Sean Hunziker  
(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.